Autologous hematopoietic SCT (AHSCT) has been investigated in the past as a therapeutic alternative for multiple sclerosis (MS). Despite advances in clinical management, knowledge about mechanisms involved with clinical remission post transplantation is still limited. Abnormal microRNA and gene expression patterns were described in MS and have been suggested as disease biomarkers and potential therapeutic targets. Here we assessed T-and B-cell reconstitution, microRNAs and immunoregulatory gene expression after AHSCT. + and CD8 + T cells from MS patients presented upregulated miR-16, miR-155 and miR-142-3p and downregulated FOXP3, FOXO1, PDCD1 and IRF2BP2. After transplantation, the expression of FOXP3, FOXO1, PDCD1 and IRF2BP2 increased, reaching control levels at 2 years. Expression of miR-16, miR-155 and miR-142-3p decreased towards normal levels at 6 months post therapy, remaining downregulated until the end of follow-up. These data strongly suggest that AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT.
INTRODUCTION
In recent years, autologous hematopoietic SCT (AHSCT) has been found to be able to suppress inflammatory activity in patients with multiple sclerosis (MS) and induce sustained disease control. [1] [2] [3] Clinical remission after AHSCT depends on qualitative immunological changes that promote immune tolerance. Restoration of the CD4 + CD25
+ regulatory T-cell (Treg) immune compartment 4, 5 and profound resetting of the adaptive immune system 6 have been described. Suppression of inflammatory activity in MS patients undergoing AHSCT does not depend on persisting lymphopenia and is associated with de novo regeneration of the T-cell repertoire. 7, 8 Additionally, decreased T-helper type 17 response 9 and depletion of IL-17-producing mucosal-associated invariant T cells have been shown after AHSCT in MS patients. 10 Autoimmune diseases such as MS result from failure of tolerance mechanisms to prevent the expansion of pathogenic T cells. Dysfunctional CD4 + CD25 hi Tregs 11 and abnormalities in FOXP3 mRNA and protein expressions in peripheral T cells 12 are described as part of this scenario. In recent years, microRNAs (miRNAs/miRs) have emerged as an important gene expression controller in health and disease.
MiRNAs are small noncoding RNA molecules that modulate the expression of multiple protein-encoding genes at the posttranscriptional level and are involved in the regulation of immunity, among other functions. 13, 14 Loss or dysregulation of certain individual miRNAs severely compromises immune development and response, and may lead to disorders such as autoimmunity and cancer. 15 Abnormal miRNA function has been detected in several human diseases, including MS, 16 and is suggested as a disease biomarker and a potential therapeutic target. 15 In MS patients, aberrant expression of miR-16, 17 miR-155 18 and miR-142-3p 19 has been described. These miRNAs are involved in the regulation of T-cell activation, and their overexpression is related to T-cell-mediated autoimmune inflammation. 13, 14 Moreover, they control Treg function and the expression of FOXP3, 20, 21 an important gene involved with self-tolerance.
In the context of AHSCT, molecular mechanisms underlying clinical effectiveness are poorly understood. 22 In our study, we demonstrate, for the first time, that AHSCT promotes persistent downregulation of disease-related miRs, while increasing the expression of their predicted target genes. Moreover, we detected increased Treg counts, with higher expression of immunoregulatory molecules. In the context of homeostatic expansion and absence of thymic reactivation in the two first years that follow AHSCT, we propose that regulatory cells are in fact non-regulatory cells that express FOXP3 under the influence of normalized miR expression.
Our results thus suggest that clinical remission in MS patients after AHSCT may be associated with improvement of immunoregulatory mechanisms.
PATIENTS AND METHODS

MS patients and transplant protocol
Twenty-four MS patients refractory to first-line therapy were selected for AHSCT. The protocol was approved by the National Ethics Committee and all patients signed informed consent. Detailed inclusion and exclusion criteria, mobilization regimens and clinical evaluations have been reported previously. 23 Briefly, the immunoablative transplant conditioning included four doses of CY (50 mg/kg on days − 5, − 4, − 3 and − 2) and rabbit antithymocyte globulin (thymoglobulin; Genzyme, Cambridge, MA, USA) (4.5 mg/kg divided in days − 5 to − 1) followed by infusion of unmanipulated peripherally collected autologous CD34 + cells, mobilized with 2 g/m 2 CY and granulocyte-colony-stimulating factor. Demographic, clinical and follow-up data from all patients are listed in Table 1 .
After AHSCT, patient follow-up included clinical assessments of general health and of neurological disability through the Expanded Disability Status Scale (EDSS) and magnetic resonance imaging (MRI). Blood was drawn at each appointment for immunological monitoring. For this present study, clinical and immunological data were obtained within the first 2 years after AHSCT.
Blood samples from nine age-and sex-matched healthy controls were analyzed for gene and miRNA expression. 
MO, USA). CD4
+ and CD8 + T lymphocytes were isolated by positive selection using magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of the obtained cell subsets was checked by flow cytometry and was found to be 495%.
RNA extraction and real-time PCR. Total RNA was extracted from CD4 + and CD8 + T cells by Trizol (Invitrogen, Carlsbad, CA, USA) method, according to the manufacturer's instructions. RNA quantity and quality were verified using NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA) and 1% agarose gel electrophoresis.
TaqMan assays were used for quantitative analysis of mature miRNA and gene expression, as well as endogenous controls. Further information is provided as Supplementary Data. Expression values were calculated using the 2 − ΔCt method. 24 
Statistical analysis
Immune reconstitution data were compared by linear regression model with mixed effects (random and fixed effects) using the post test by orthogonal contrasts. For variable frequency, we used a logarithmic transformation to make the data fit the proposed model. Adjustments were made using the PROC MIXED (SAS 9.0 software, Cary, NC, USA + CD4 + and CD3 + CD8 + T cells of one representative patient (e). The boundaries of the boxes indicate the 25th and 75th percentiles, the lines within the boxes indicate the median and the whiskers mark the 10th and the 90th percentiles. Bars represent mean ± s.d. Mixed linear regression model was used as statistical test. PreTx, n = 14; 6 months (6 mo), n = 7; 12 months (12 mo), n = 9; 24 months (24 mo), n = 12.
analyses and graphical presentations, we used GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) software for Mac OS X.
RESULTS
Clinical evaluations after AHSCT
All twenty-four patients successfully completed the proposed treatment protocol. Before and after AHSCT clinical data are summarized in Table 1 . Only one patient (MS 12) presented acute inflammatory lesions (gadolinium-enhancing lesions) on MRI at 1.5 years post transplantation, with subsequent neurological worsening, quantified by EDSS, at the 2 years post therapy time point. The remaining patients were free of relapses for mean follow-up of 22.25 months (range: 6-24 months) after AHSCT, in the absence of any immunosuppressive or modulatory treatment.
Leukocyte recovery Total and T lymphocytes recovered at 6 months and 1 year post transplantation, respectively (Supplementary Figures 1A and B) . No reconstitution of CD4 + T-cell counts to pretransplant levels was observed until the end of the 2-year follow-up. In contrast, CD8 + T-cell counts did not change during the first year, becoming higher than baseline only at 2 years after AHSCT, leading to reduction of CD4/CD8 ratios ( Supplementary Figures 1C-E) . Additionally, B-cell counts reconstituted to baseline values at 6 months, achieving higher levels at 2 years posttransplantation (Supplementary Figure 1F) .
Immune reconstitution by peripheral T-cell expansion To determine changes in specific CD4 and CD8 sub-populations, we evaluated the naive (T naive ), central-memory (T CM ) and effectormemory (T EM ) T-cell reconstitution after AHSCT. As expected, highdose immunosuppression reduced CD4 + T CM cell counts during the entire follow-up (Figure 1c) . Conversely, CD8
+ T CM counts increased within the first year of follow-up (Figure 1d Figure 2A) , while the recent thymic emigrant/CD3 + CD4 + proportion did not change (Supplementary Figure 2B) .
Collectively, these results show that during the first 2 years after AHSCT, reconstitution of circulating T-cell pool is mainly due to expansion of remaining peripheral T cells.
Transient increase in exhausted T cells and higher PD-1 expression PD-1 is a costimulatory molecule expressed in exhausted dysfunctional T cells and has an important role in the regulation of immune response. 25 PD-1 increases IL-10 production, promoting lower proliferation and increased apoptosis of myelin basic protein-specific cells. Therefore, PD-1 is associated with disease remission in MS patients. 26 We observed that CD3 Figure 3) .
These results show transient increase of exhausted T cells and higher PD-1 expression at 6 months post transplantation, probably as result of persistent self-Ag stimulation in the lymphopenic environment that immediately follows transplantation. 25 In this context, Thangavelu et al. 27 describe that PD-1 expression is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis after AHSCT, and may contribute to clinical remission. − cells of one representative patient. Statistical test performed was mixed linear regression model. PreTx, n = 21; 6 months (6 mo), n = 13; 12 months (12 mo), n = 10; 24 months (24 mo), n = 13. been shown to increase in the PB of MS patients after AHSCT. 8, 10 Indeed, in our study, we observed significantly increased values of CD8 + CD28 − CD57 + suppressor T cells at 6 and 12 months post transplantation when compared with baseline, possibly indicating that the lymphopenic environment promotes an oligoclonal expansion of these cells (Figure 3) .
Immunoregulatory cell kinetics
Treg numbers were elevated at 1 and 2 years after AHSCT (Figure 4a Figure 1C) , Treg/CD4 + ratios (%) increased from (mean ± s.d.) 0.92 ± 1.2% at baseline to 2.64 ± 2.98% at 6 months (P = 0.025), 3.64 ± 2.02% at 12 months (P o0.001) and 5.33 ± 3.73% at 24 months (P o 0.001) after AHSCT (Supplementary Figure 4) . Furthermore, GITR (glucocorticoid-induced TNFR) expression on CD4 + CD25 hi T cells also increased (Figure 4b ), achieving maximum values at 2 years after AHSCT. In parallel, we also observed a significant increase in CTLA-4 expression on CD4 + CD25 hi T cells, starting at 6 months until the end of follow-up (Figure 4c) .
Altogether, these results demonstrate that AHSCT leads to the expansion of peripheral immunoregulatory cells and to a shift towards a more immunosuppressive phenotype of CD4 + CD25 hi T cells. These immunological changes may be associated with the restoration of self-tolerance and clinical remission promoted by the procedure.
Upregulated miR-16, miR-155 and miR-142-3p expression normalized after AHSCT Aberrant expression of miRNAs can lead to autoinflammatory events and contribute to MS development. 16 Altered miRNA expressions have been proposed as biomarkers of the disease, and conventional treatment has been shown to restore the expression of dysregulated miRNAs in MS. 19 reported in MS, we decided to evaluate the expression of these miRNAs in our transplanted patients.
At baseline, MS patients presented higher expression of miR-16, miR-155 and miR-142-3p in CD4 + and CD8 + T cells, when compared with healthy donors (P o0.001; Figure 5 ). After AHSCT, the expression of these miRNAs normalized at 6 months and remained stable until the end of the evaluation period (P o 0.001; Figure 5 ). The boundaries of the boxes indicate the 25th and 75th percentiles, the lines within the boxes indicate the median and the whiskers mark the 10th and the 90th percentiles. Statistical test performed was one-way analysis of variance. Pretransplantation (PreTx), n = 9; 6 months (6 mo), n = 9; 12 months (12 mo), n = 9; 24 months (24 mo), n = 9; healthy controls (HC), n = 9. NS, nonsignificant.
Immunoregulatory FOXP3, FOXO1, PDCD1 and IRF2BP2 gene expression normalized after AHSCT Once downregulation and normalization of miR-16, miR-155 and miR-142-3p expressions were detected after transplantation, we investigated changes in expression of their predicted target genes, identified according to available electronic databases (http://www.targetscan.org and http://www.mirbase.org). FOXP3 (miR-155 predicted target; expression controlled by miR-16), 20 FOXO1 (miR-142-3p predicted target), PDCD1 (miR-16 predicted target) and IRF2BP2 (miR-155 predicted target) were selected for quantification of expression by RT-PCR. Other genes were not analyzed owing to limitations in sample size.
MS patients presented low expression of FOXP3, FOXO1, PDCD1 and IRF2BP2 in CD4 + and CD8 + T cells at baseline (P o 0.001; Figure 6 ). At 2 years after AHSCT, these genes had their expression increased (P o0.001; Figure 6 ) to healthy control levels. The boundaries of the boxes indicate the 25th and 75th percentiles, the lines within the boxes indicate the median and the whiskers mark the 10th and the 90th percentiles. Statistical test performed was one-way analysis of variance. Pretransplantation (PreTx), n = 12; 12 months (12 mo), n = 11; 24 months (24 mo), n = 11; healthy controls (HC), n = 9. NS, nonsignificant.
DISCUSSION
Elimination of autoreactive cells, thymic reactivation and restoration of regulatory processes are described as the main therapeutic mechanisms of AHSCT for autoimmune disease, including MS. [4] [5] [6] [7] [8] [9] [10] Combined, they promote control of autoimmunity and clinical amelioration. 30, 31 In MS, Muraro et al. 7, 8 showed installation of a new and diverse T-cell receptor (TCR) repertoire and thymic reactivation after AHSCT. Other groups have reported similar findings, including in different autoimmune diseases. 6, 9, 10, 32 To further explore immunological mechanisms of AHSCT and improve clinical applications of this therapy, we studied Treg reconstitution, miR and gene expression.
Aberrant expression of miR-155, 18 miR-142-3p 19 and miR-16 17 has been previously reported in MS patients. However, only two studies have accessed the effects of MS therapies upon miRNA expression. 19, 33 Here, we report, for the first time, that AHSCT induces normalization of miR-155, miR-142-3p and miR-16 expression, sustained for at least 2 years of follow-up.
Paraboschi et al. 18 described higher levels of miR-155 in MS patients when compared with healthy controls, showing the importance of this miRNA in MS pathogenesis. Additionally, miR-155-knockout mice do not develop experimental autoimmune encephalomyelitis. 34 In our study, expression of miR-155 was steadily downregulated after AHSCT, reaching healthy control levels. FOXP3 and IRF2BP2 are predicted targets of miR-155, and consequently modulated by its expression. As expected, we detected increased expression of miR-155 target genes after transplantation, indicating that AHSCT might contribute to improve the immunoregulatory network.
Similarly, aberrant expression of miR-142-3p has been reported in MS patients. 19 MiR-142-3p inhibits Treg-suppressive activity 21 and can also modulate the expression of its target gene, FOXO1.
Here, we were able to show strong downregulation of miR-142-3p expression after AHSCT, followed by increased expression of FOXO1, both reaching healthy control levels. Upregulation of miR-16 has been shown in MS patients. 17 Moreover, miR-16 overexpression promoted inhibition of FOXP3 in Tregs, thereby modifying them to a more conventional T-celllike function. 20 On the other hand, silencing of miR-16 pathway in conventional T cells may lead to an inducible Treg-like function by stimulating FOXP3 and CTLA-4 expression. 20 This dynamic behavior corroborates our results, once we observed a switch from 'high-miR-16 low-FOXP3' to 'low-miR-16 high-FOXP3' expression.
PD-1/miR-155-double-knockout mice are more susceptible to experimental autoimmune encephalomyelitis, whereas PD-1-knockout mice accumulate CD4 + T cells in the brain. 35 We believe that increased PDCD1 expression after AHSCT may be due to the downregulation of miR-16, as PDCD1 is one its predicted target genes.
Reduced expression of IRF-1 and IRF-2 mRNAs has been reported in untreated patients with active MS. 36 Low levels of these regulatory factors could affect the feedback control of multiple IFN-stimulated genes, leading to chaotic cytokine response and inflammation. Therefore, normalization of IRF2BP2 gene expression after AHSCT may be associated with the clinical remission achieved by most patients post therapy. However, this hypothesis must be verified by studies with longer follow-up.
We also show, for the first time, transient increase of exhausted CD3 + CD8
+ PD-1 + T cells, and higher expression of PD-1 on CD3 + CD4 + T cells after transplantation. The PD-1/PD-L1 costimulatory pathway controls lymphocyte proliferation and activation, 37, 38 and has a critical role in regulating autoimmune damage in experimental autoimmune encephalomyelitis models. 39 In MS patients, PD-1 and PD-L1 expression is associated with different patterns of disease activity. 26 Our data suggest that PD-1/PD-L1-directed strategies could be envisioned as the future therapeutic approaches for MS. Intrinsic defects in function of CD4 + CD25 hi Tregs have already been described in MS patients, 11 suggesting that impairment of the immunoregulation may be associated with MS pathophysiology. Improvement of regulatory function is already established as part of the beneficial effects of autologous transplantation. 4, 5, 40 Indeed, in our MS patients AHSCT increased Treg counts from the first year until the 2-year follow-up. Furthermore, CD4 + CD25
hi Tregs presented higher expression of immunoregulatory molecules after AHSCT, which may have contributed to restore selftolerance and to control autoimmunity. CTLA-4 expression regulates Treg function and is clearly associated with the immunosuppressive potential. 41 The same is reported for GITR expression, which modulates Treg-suppressive capacity in autoimmunity and contributes to peripheral tolerance. 42 Additionally, expansion of CD8 + CD28 − CD57 + suppressor T cells has been previously reported in transplanted MS patients. 8, 10 Here, we confirm that these cells undergo oligoclonal expansion in the initial periods of lymphopenic environment.
Current discussions about the use of more or less myeloablative conditioning regimens are still unsettled. 43 Different conditioning regimens may diversely affect the immune system. [8] [9] [10] Mechanistic evaluations on the effects of AHSCT for MS are limited to thymic recovery and regulatory T-cell reconstitution. To our knowledge, this is the first study to address gene and miR expression in MS after transplantation. Therefore, whether the chosen conditioning regimen affects genes and miRNAs differently than others remains still to be answered.
Altogether, we demonstrate that AHSCT can induce epigenetic changes, thereby improving the immunoregulatory network in MS. Longer follow-up is warranted to further correlate immunological alterations with clinical outcomes. Nevertheless, our results indicate that targeting miR-16, miR-155 and miR-142-3p could represent a valid future therapeutic option for MS and perhaps for other autoimmune diseases.
